PMID- 27337740
OWN - NLM
STAT- MEDLINE
DCOM- 20170120
LR  - 20200219
IS  - 2561-8741 (Electronic)
IS  - 2561-8741 (Linking)
VI  - 23
IP  - 1
DP  - 2016
TI  - Canadian cost analysis comparing maintenance therapy with bortezomib versus 
      lenalidomide for patients with multiple myeloma post autologous stem cell 
      transplant.
PG  - e103-13
AB  - BACKGROUND: Multiple myeloma (MM) is a cancer caused by malignant plasma cells 
      that accumulate mostly in the bone marrow. In Canada, the most common maintenance 
      therapy options after autologous stem cell transplant (ASCT) are bortezomib and 
      lenalidomide. OBJECTIVE: To determine the incremental cost between bortezomib and 
      lenalidomide maintenance therapies for patients with MM post ASCT. METHODS: 
      Analyses were conducted to compare the annual costs of bortezomib and 
      lenalidomide maintenance treatments for patients with MM post ASCT in Canada. The 
      base case analysis included the acquisition costs of the drugs and administration 
      costs. Additional analyses were conducted which considered the cost of 
      experiencing adverse events (AEs) and the cost of treating second primary 
      malignancies (SPMs). RESULTS: In the Canadian healthcare system, the total annual 
      per patient cost was $33,967 for bortezomib maintenance therapy versus $131,765 
      for lenalidomide maintenance therapy. One-way sensitivity analyses demonstrated 
      that both AEs and SPMs had little impact on the incremental cost, and that 
      differences between the two maintenance therapies were mainly due to the 
      acquisition costs of the drugs. CONCLUSIONS: Bortezomib is significantly less 
      costly than lenalidomide, and is an economically reasonable maintenance treatment 
      option for patients with MM post ASCT.
FAU - LeBlanc, R
AU  - LeBlanc R
FAU - Hollmann, S
AU  - Hollmann S
FAU - Tay, J
AU  - Tay J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160607
PL  - Australia
TA  - J Popul Ther Clin Pharmacol
JT  - Journal of population therapeutics and clinical pharmacology = Journal de la 
      therapeutique des populations et de la pharmacologie clinique
JID - 101530023
RN  - 0 (Antineoplastic Agents)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 69G8BD63PP (Bortezomib)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/*economics
MH  - Bortezomib/administration & dosage/*economics
MH  - Canada
MH  - Combined Modality Therapy
MH  - Costs and Cost Analysis/*methods
MH  - Follow-Up Studies
MH  - Hematopoietic Stem Cell Transplantation/*economics
MH  - Humans
MH  - Lenalidomide
MH  - Multiple Myeloma/*economics/therapy
MH  - Thalidomide/administration & dosage/*analogs & derivatives/economics
MH  - Transplantation, Autologous
EDAT- 2016/06/24 06:00
MHDA- 2017/01/21 06:00
CRDT- 2016/06/24 06:00
PHST- 2016/06/24 06:00 [entrez]
PHST- 2016/06/24 06:00 [pubmed]
PHST- 2017/01/21 06:00 [medline]
PST - ppublish
SO  - J Popul Ther Clin Pharmacol. 2016;23(1):e103-13. Epub 2016 Jun 7.